Pediatric Eustachian Tube Dilatation in the Management of Mesotympanic Retraction With Effusion. (PED-MR)
Pediatric Eustachian Tube Dilatation in the Management of Mesotympanic Retraction With Effusion: a Multicenter Randomized Study Versus Standard Treatment.
The goal of this clinical investigation is to evaluate the effectiveness of ETD + standard treatment versus standard treatment only, on the improvement of the tympanic membrane retraction, up to 18 months after intervention in children aged ]8-17[ with posterior mesotympanic retraction and middle ear effusion.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Fabian BLANC, Dr
- Phone Number: +33 0668248182
- Email: fabian-blanc@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France, 34000
- Fabian BLANC
-
Contact:
- Fabian BLANC
- Phone Number: +33 0668248182
- Email: fabian-blanc@chu-montpellier.fr
-
-
APHM
-
Marseille, APHM, France, 13005
- Richard NICOLLAS
-
Contact:
- Richard NICOLLAS, PhD
- Phone Number: +33 0491386709
- Email: richard.nicollas@ap-hm.fr
-
-
APHP Hôpital Necker
-
Paris, APHP Hôpital Necker, France, 75006
- François SIMON
-
Contact:
- François SIMON, PhD
- Phone Number: +33 0153104600
- Email: f.simon@aphp.fr
-
-
APHP Hôpital Robert Debre
-
Paris, APHP Hôpital Robert Debre, France, 75019
- Thiery VAN DEN ABBEELE
-
Contact:
- Thiery VAN DEN ABBEELE, PhD
- Phone Number: +33 0140032179
- Email: thierry.van-den-abbeele@aphp.fr
-
Sub-Investigator:
- Natacha TEISSIER, PhD
-
Sub-Investigator:
- Charlotte BENOIT, Dr
-
Sub-Investigator:
- Emilie BOIS, Dr
-
-
HCL Hôptial Femme Mere Enfant
-
Lyon, HCL Hôptial Femme Mere Enfant, France, 69677
- Sonia AYARI
-
Contact:
- Sonia AYARI, PhD
- Phone Number: +33 0427855729
- Email: sonia.ayari-khalfallah@chu-lyon.fr
-
Sub-Investigator:
- Aurélie COUDERT, Dr
-
Sub-Investigator:
- Maxime TABEY, Dr
-
-
Hôpital Purpan
-
Toulouse, Hôpital Purpan, France, 40031
- Marie-Noël CALMELS
-
Contact:
- Marie-Noël CALMES, PhD
- Phone Number: +33 0561779009
- Email: calmels.mn@chu-toulouse.fr
-
Sub-Investigator:
- Blandine BALADI
-
Sub-Investigator:
- Yohan GALLOIS
-
-
Hôpital Salengro
-
Lille, Hôpital Salengro, France, 5900
- Philippine TOULEMONDE
-
Contact:
- Philippine TOULEMONDE, Dr
- Phone Number: +33 0320446205
- Email: philippine.toulemonde@chu-lille.fr
-
Sub-Investigator:
- Hugo DELERRY
-
Sub-Investigator:
- Christophe VINCENT
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged strictly between 8 and 17 years of age
- Presenting a posterior mesotympanic retraction (grade II or III without adherence to the promontory from Sade's grade) with effusion
Exclusion Criteria:
- Weight strictly less than 20kg
- Down syndrome
- Craniosynostosis and other head and neck malformations
- History of skull base surgery
- History of skull fracture
- Failure to obtain consent
- Non-affiliation to a social security scheme
- Persons placed under legal protection
- Person participating in another research including a period of exclusion still in progress
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Eustachian tube dilation added to standard treatment
Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present. ETD involves using a transnasal balloon catheter, during general anesthesia, by the surgeon in charge of the patient. The device will be an Acclarent Aera 6x16 mm balloon, with a pressure set at 12 atm for 2 minutes in the eustachian tube. The manufacturer of the ETD device will organize a training session with hands-on on simulator, for all the principal investigators prior to the start of the study, to ensure homogenous intervention. |
Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical, coupled with the Acclarent Aera™ Eustachian Tube Balloon Dilation System. |
|
Active Comparator: Standard treatment
Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present, during general anesthesia, by the surgeon in charge of the patient. Tube placement will be in the anterior or inferior part of the tympanic membrane. Different design and brand of tympanostomy tube exist and are used in the different centers, leading to putative slightly different outcomes in term of adverse events related to the tympanostomy tube and duration. To decrease the cohort's heterogeneity, we propose to utilize the same tympanostomy tube for all the patients included in the study (Shepard's tympanostomy tube). |
Medical device: Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tympanic membrane retraction
Time Frame: Tympanic membrane retraction will be assessed 3 times during the follow up: at 6, 12 and 18 months.
|
The assessment of tympanic membrane retraction is treated as a survival variable. Tympanic membrane retraction will be blindly assessed by an adjudication committee, through recorded otoendoscopy, based on the Sade's classification (in grade 0, I, II, III, IV, or V). The delay will be calculated as the time from intervention to improvement in tympanic membrane retraction (event), to loss of follow up (censoring), or to the study endpoint (censoring). |
Tympanic membrane retraction will be assessed 3 times during the follow up: at 6, 12 and 18 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mesotympanic retractation
Time Frame: 6, 12 and 18 months
|
Mesotympanic retractation according to Sade's classification |
6, 12 and 18 months
|
|
Audiometry thresholds
Time Frame: 6, 12 and 18 months
|
Mean of the air-bone gap at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz |
6, 12 and 18 months
|
|
Tympanometry profile
Time Frame: 6, 12 and 18 months
|
Tympanometry profile (A, B or C) |
6, 12 and 18 months
|
|
The quality of life
Time Frame: 6, 12 and 18 months
|
Quality of Life measured through the OM-6 questionnaires |
6, 12 and 18 months
|
|
The quality of life
Time Frame: 6, 12 and 18 months
|
Quality of Life measured through the PedsQL™ 4.0 questionnaires |
6, 12 and 18 months
|
|
Adverse events in both arms
Time Frame: during the first week
|
Occurrence of adverse events and serious events during the first week, coded according to MedDRA. |
during the first week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Fabian BLANC, Dr, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RECHMPL26_0029
- 2026-A01144-47 (Other Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.